Skip to main
PYPD
PYPD logo

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid Ltd is advancing its lead product candidate, D-PLEX100, which has demonstrated significant efficacy in reducing surgical site infections (SSIs) and mortality by 54% when combined with standard-of-care in patients with extensive incision lengths. The ongoing SHIELD II trial is expected to yield a favorable interim analysis, with the potential for early halting and subsequent filing for regulatory approval based on strong preliminary data. Financial projections indicate a decreasing net loss per share from $4.83 in 2024 to $2.41 in 2025, reflecting potential improvement in the company's financial position as clinical milestones are achieved.

Bears say

PolyPid Ltd faces a negative outlook primarily due to ongoing financial losses, exemplified by a reported third-quarter net loss of $1.22 per share, which exceeded expectations and was driven by higher-than-anticipated research and development expenditures. Additionally, the company's commercial risks are exacerbated by competition and pricing pressures, along with geopolitical tensions in the Middle East, which may disrupt operations. Lastly, the uncertainties surrounding the Phase 3 SHIELD II trial of D-PLEX100 and potential dilution risks further contribute to concerns regarding the company's financial stability and outlook.

PolyPid (PYPD) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Buy based on their latest research and market trends.

According to 9 analysts, PolyPid (PYPD) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.